Orgenesis Announces Proposed Underwritten Public Offering; No Size Or Amount Disclosed
Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced it has commenced an underwritten public offering. Orgenesis intends to use the net proceeds from the offering for working capital and general corporate purposes.
EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering.
The proposed offering of the units, consisting of one share of common stock and one warrant to purchase one share of common stock, and pre-funded units, consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, is being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-254806), which was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on April 7, 2021, and the accompanying prospectus contained therein.
The offering is being made only by means of a preliminary prospectus supplement and accompanying prospectus. A final prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement.